Viridian Therapeutics Discloses 'Exciting' Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety

By Yahoo! Finance | Sep 10, 2024 at 09:24 AM EST

Viridian Therapeutics released positive data from the THRIVE phase 3 trial of VRDN-001 for thyroid eye disease. Veligrotug showed significant improvements in key disease endpoints, with promising results and minimal adverse events.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.